427 material Form 8-K filings that 376 companies we cover made with the SEC in September 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Dexcom said CEO and Chairman Kevin R. Sayer is on a temporary medical leave effective September 14, 2025. The board named President and COO Jacob S. Leach as interim principal executive officer and Lead Independent Director Mark Foletta as interim chairman; neither will receive extra pay for the interim roles.
Kevin R. Sayer, CEO and Chairman, began a temporary medical leave effective September 14, 2025.
Jacob S. Leach, President and Chief Operating Officer, is interim principal executive officer in addition to his current duties.
Mark Foletta, Lead Independent Director, is interim chairman of the Board.
Leach and Foletta will not receive additional compensation for the interim appointments.
Cohen & Steers said Chief Financial Officer Raja Dakkuri will resign effective October 17, 2025, after securing another opportunity, and that the resignation was not due to any disagreement with the company. Controller Michael Donohue will become interim CFO on that date while keeping his controller role, and the company has started a search for a permanent successor. The filing does not report any financial results, but the change in the finance leadership team is relevant to shareholders.
Raja Dakkuri gave notice on September 11, 2025, and remains CFO through October 17, 2025.
Michael Donohue, Senior Vice President and Controller since May 2023, becomes interim CFO effective October 17, 2025.
Donohue's interim CFO bonus totals $300,000: $150,000 in cash payable in Q1 2026 and restricted stock units equal to $150,000 at the October 17, 2025 closing price, vesting over four years.
The company has begun a search for a permanent CFO that includes internal and external candidates.
Crown Castle said Christian H. Hillabrant began work as President and Chief Executive Officer on September 15, 2025, after the Board previously appointed him in an August 4, 2025 disclosure. The Board also expanded its size to 10 members and appointed him as a director effective the same day.
Christian H. Hillabrant became President and CEO and a director effective September 15, 2025.
The Board expanded from its prior size to 10 members, effective immediately before the appointment.
The filing states no arrangement with other persons for his board selection and no related party transactions reportable under Item 404(a).
Neogen said Chief Financial Officer and Chief Operating Officer David Naemura intends to resign to pursue other opportunities, and that the decision is not due to any disagreement over operations, financial statements, accounting policies or internal controls. He will stay in both roles until his departure, expected between the October 10-Q filing and December 31, 2025, and will help onboard a new CFO, a search for whom is underway with an executive search firm. Shareholders face a leadership transition in the finance function, with a successor not yet named.
Naemura communicated his intention to resign to the company on September 12, 2025.
Departure expected after the Form 10-Q filing in October 2025 and no later than December 31, 2025.
If he remains employed through December 31, 2025, he is eligible for 50% of his annual target cash bonus under the transition agreement.
Jim Walter, Vice President of Global Operations, will oversee Global Procurement in addition to his current duties.
On September 15, 2025, TKO Holdings amended its first lien credit agreement and borrowed the full $1.0 billion incremental term loan, maturing November 21, 2031. The proceeds are intended mainly to fund share repurchases, including $800.0 million under an accelerated share repurchase agreement with Morgan Stanley and up to $174.0 million under a 10b5-1 trading plan, which would leave the company with $1.0 billion remaining under its $2.0 billion repurchase program.
$1.0 billion incremental term loan borrowed September 15, 2025, priced at Term SOFR plus 2.00%
$800.0 million accelerated share repurchase with Morgan Stanley; $800.0 million payment due September 16, 2025, with completion expected December 2025
Up to $174.0 million in repurchases under a 10b5-1 plan, to start after the accelerated share repurchase is completed
Revolving credit facility maturity extended to September 15, 2030
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.